CoronaryAtlas logo
CoronaryAtlas
antithrombin III
Pathway / Coagulation & thrombus formation

antithrombin III

SERPINC1protein

Antithrombin III is consumed during thrombin-driven thrombus formation, and its depletion indicates active coagulation in acute infarction.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencemedium
RationaleCoagulation inhibitor; depleted during thrombosis; consumed in AMI thrombus formation.
Druggability
DruggableYes
Known drugs / candidates12
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000117601

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
50
A — assay feasibility
84
E — evidence strength
86
T1DI (composite)
24
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 0
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuremag 2
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 2
4bstent thrombosismag 1
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 17 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
Chromogenic anti-Xa or anti-IIa activity
Reagent / substrate
Factor Xa/IIa excess + chromogenic substrate; heparin cofactor
Platform
Coagulation analyzer
Turnaround · availability
Routine–send-out · Clinical

Human genetic evidence

0.603
Open Targets association (myocardial_infarction)

Literature evidence(19)